Eyenovia Inc is a biotechnology company focused on developing innovative ophthalmic therapeutics utilizing its proprietary delivery technology. The company aims to enhance the treatment of various eye conditions through its advanced product pipeline, which includes specialty pharmaceutical formulations designed to improve the efficacy and patient compliance of eye care treatments. Eyenovia’s pioneering approach leverages microdosing technology to deliver medications more precisely and effectively, potentially transforming the landscape of ocular therapeutics and improving outcomes for patients with vision-related ailments. Read More
Eyenovia amended its loan with Avenue Capital, changing stock conversion option terms. New rules cap lender ownership and protect rights during major corporate fundamental transactions.
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
From $30 million Solana, Bitcoin staking and rare cancer breakthroughs to critical minerals exploration and transformative mergers, these companies—are reshaping the landscape of blockchain, biotech, digital health, and resource innovation. Investors should closely monitor these stocks as catalysts unfold across global markets.
PALM BEACH, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The Retinal and Fundis Camera market has shown growth in the recent years and is expected to continue for years to come. Fundus cameras are sophisticated instruments utilized in ophthalmology for capturing detailed images of the retina. They employ a specialized optical design akin to an indirect ophthalmoscope, with the angle of view being a key parameter defining their functionality… Fundus photography enables physicians to meticulously examine retinal changes over time, facilitating collaboration among colleagues and enhancing patient care. A recent report from Precedence Research said: “The fundus cameras market experiences growth driven by the evolving landscape of imaging technologies, particularly in diagnosing age-related macular degeneration (AMD). Traditionally, fundus photography with film-based cameras, preferably through pharmacologically dilated pupils, has been pivotal in documenting AMD severity. The emergence of high-resolution digital cameras presents new opportunities in the market. Comparisons among different imaging systems, including nonstereoscopic color retinal images taken with digital cameras through dark-adapted and dilated pupils, as well as stereoscopic images captured with standard film cameras, highlight the expanding applications of fundus cameras. Such comparisons underscore the need for versatile imaging solutions to accommodate diverse clinical scenarios, thus fueling the growth in the fundus cameras market.” Active healthcare/tech companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Outlook Therapeutics, Inc. (NASDAQ: OTLK), Eyenovia, Inc. (NASDAQ: EYEN), Bausch + Lomb Corporation (NYSE: BLCO), Biomea Fusion, Inc. (NASDAQ: BMEA).
Peraso Inc. (NASDAQ: PRSO), a leading innovator in mmWave wireless technology, is capturing attention across both the trading floor and the defense sector as its stock enters a technically strategic inflection point. With a recent spike to $1.20 and trading volume surging 64% above its 30-day average, the signals point to an under-the-radar accumulation phase, potentially driven by institutional investors.
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.
Eyenovia shares surged on merger progress with Betaliq and improved Q1 financials. They extended merger talks and reported a narrower net loss due to restructuring.
